Regulatory & Safety

(Image: Getty/Seb_Ra)

BMS-Celgene mega-merger receives shareholder nod

By Ben Hargreaves

The $74bn deal appeared to be fraying around edges, as certain shareholders voiced dissent, but a vote saw the deal pass with support from more than 75% of investors.

(Image: Getty/Bedo)

The most read stories in March

By Staff Reporter

After the M&A excitement that began the year, the developments in March were a mixture of long-running events, such as the sartan manufacturing issues, breakthrough research and regulatory struggles.